IP Library Granted Patent US 8,000,948
Granted Patent B2
US 8,000,948 · App. 10/518,103 · Granted Aug 16, 2011

Methods for identifying compounds for treating disease states

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,000,948
App. No.
10/518,103
Granted
Aug 16, 2011
Kind
B2
Abstract

The process of System Reconstruction is used to integrate sequence data, clinical data, experimental data, and literature into functional models of disease pathways. System Reconstruction models serve as informational “skeletons” for integrating various types of “high throughput” data.

Claims (47)

1. A computer-implemented method for reconstructing human metabolism in a non-disease state and a disease state, said method comprising:

(a) collecting metabolic data for said non-disease and disease states;

(b) linking the data into metabolic pathways using a relational database;

(c) ranking the metabolic pathways based on their relevance to human metabolism, wherein the ranking of the metabolic pathways comprises assigning each pathway to one of the following categories, from the most relevant to the least relevant to human metabolism:

(i) a multi-step pathway wherein all of the reactions are catalyzed by known human enzymes and/or enzymes that have open reading frame (ORF) candidates in the human genome;

(ii) a multi-step pathway wherein not all of the reactions are catalyzed by known human enzymes and/or enzymes that have ORF candidates in the human genome; and

(iii) a single step pathway;

(d) linking said ranked metabolic pathways to functional information, disease manifestations and/or high-throughput screening information;

(e) identifying interconnections between the ranked metabolic pathways; and

(f) reconstructing human metabolism in said non-disease and disease states on the basis of information obtained in steps (a) through (e).

2. A computer-implemented method for identifying a human drug target, said method comprising:

(a) collecting metabolic data for a non-disease state and a disease state;

(b) linking the data into metabolic pathways using a relational database;

(c) ranking the metabolic pathways based on their relevance to human metabolism, wherein the ranking of the metabolic pathways comprises assigning each pathway to one of the following categories, from the most relevant to the least relevant to human metabolism:

(i) a multi-step pathway wherein all of the reactions are catalyzed by known human enzymes and/or enzymes that have open reading frame (ORF) candidates in the human genome;

(ii) a multi-step pathway wherein not all of the reactions are catalyzed by known human enzymes and/or enzymes that have ORF candidates in the human genome; and

(iii) a single step pathway;

(d) linking said ranked metabolic pathways to functional information, disease manifestations and/or high-throughput screening information;

(e) identifying interconnections between the ranked metabolic pathways;

(f) reconstructing human metabolism in said non-disease and disease states on the basis of information obtained in steps (a) through (e); and

(g) identifying a human drug target by comparing differences between said non-disease and disease states using the reconstruction of step (f).

3. The method of claim 1 , wherein said metabolic data comprises expressed sequence tag data.

4. The method of claim 1 , wherein said metabolic data comprises biochemical units comprising metabolic steps, chemical compounds, reactions and/or enzymatic functions.

5. The method of claim 4 , wherein said enzymatic functions comprise genes and proteins.

6. The method of claim 4 , wherein each of said biochemical units is linked to an annotation table, said annotation table comprising at least one field.

7. The method of claim 6 , wherein said at least one field is selected from the group consisting of organ localization, tissue localization, intracellular localization, intracellular compartmentalization, subcellular localization in another organism, a relationship to a disease, and a reference to an information source.

8. The method of claim 2 , wherein said metabolic data comprises expressed sequence tag data.

9. The method of claim 2 , wherein said metabolic data comprises biochemical units comprising metabolic steps, chemical compounds, reactions and/or enzymatic functions.

10. The method of claim 9 , wherein said enzymatic functions comprise genes and proteins.

11. The method of claim 9 , wherein each of said biochemical units is linked to an annotation table, said annotation table comprising at least one field.

12. The method of claim 11 , wherein said at least one field is selected from the group consisting of organ localization, tissue localization, intracellular localization, intracellular compartmentalization, subcellular localization in another organism, a relationship to a disease, and a reference to an information source.

13. A computer-implemented method for predicting the existence of a novel human enzyme, said method comprising:

(a) collecting metabolic data in non-disease and disease states;

(b) linking the data into metabolic pathways using a relational database;

(c) ranking the metabolic pathways based on their relevance to human metabolism, wherein the ranking of the metabolic pathways comprises assigning each pathway to one of the following categories, from the most relevant to the least relevant to human metabolism:

(i) a multi-step pathway wherein all of the reactions are catalyzed by known human enzymes and/or enzymes that have open reading frame (ORF) candidates in the human genome;

(ii) a multi-step pathway wherein not all of the reactions are catalyzed by known human enzymes and/or enzymes that have ORF candidates in the human genome; and

(iii) a single step pathway;

(d) linking said ranked metabolic pathways to functional information, disease manifestations and/or high-throughput screening information;

(e) identifying interconnections between the ranked metabolic pathways;

(f) reconstructing human metabolism in said non-disease and disease states on the basis of information obtained in steps (a) through (e); and

(g) predicting the existence of a novel human enzyme by detecting a gap between non-essential metabolites that cannot be filled by any known human enzyme from the reconstructing of step (f).

14. The method of claim 13 , wherein said metabolic data comprises expressed sequence tag data.

15. The method of claim 13 , wherein said metabolic data comprises biochemical units comprising metabolic steps, chemical compounds, reactions and/or enzymatic functions.

16. The method of claim 15 , wherein said enzymatic functions comprise genes and proteins.

17. The method of claim 15 , wherein each of said biochemical units is linked to an annotation table, said annotation table comprising at least one field.

18. The method of claim 17 , wherein said at least one field is selected from the group consisting of organ localization, tissue localization, intracellular localization, intracellular compartmentalization, subcellular localization in another organism, a relationship to a disease, and a reference to an information source.

Assignments (12)
SECURITY INTEREST Recorded Dec 3, 2021
From: DECISION RESOURCES, INC.; DR/DECISION RESOURCES, LLC; CPA GLOBAL (FIP) LLC; CPA GLOBAL PATENT RESEARCH LLC; INNOGRAPHY, INC.; CAMELOT UK BIDCO LIMITED
To: WILMINGTON TRUST, NATIONAL ASSOCATION
Reel/Frame 058907/0091 →
SECURITY INTEREST Recorded Dec 17, 2019
From: CAMELOT UK BIDCO LIMITED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 051323/0875 →
SECURITY INTEREST Recorded Dec 17, 2019
From: CAMELOT UK BIDCO LIMITED
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 051323/0972 →
SECURITY INTEREST Recorded Nov 1, 2019
From: CAMELOT UK BIDCO LIMITED
To: BANK OF AMERICA, N.A.
Reel/Frame 050906/0284 →
SECURITY INTEREST Recorded Nov 1, 2019
From: CAMELOT UK BIDCO LIMITED
To: WILMINGTON TRUST, N.A. AS COLLATERAL AGENT
Reel/Frame 050906/0553 →
RELEASE OF SECURITY INTEREST Recorded Nov 1, 2019
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
To: CAMELOT UK BIDCO LIMITED
Reel/Frame 050911/0796 →
SECURITY INTEREST Recorded Oct 3, 2016
From: CAMELOT UK BIDCO LIMITED
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Reel/Frame 040205/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2016
From: THOMSON REUTERS GLOBAL RESOURCES
To: CAMELOT UK BIDCO LIMITED
Reel/Frame 040206/0448 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2015
From: THOMSON REUTERS (SCIENTIFIC) LLC
To: THOMSON REUTERS GLOBAL RESOURCES
Reel/Frame 037273/0507 →
MERGER AND CHANGE OF NAME Recorded Dec 4, 2015
From: THOMSON REUTERS (SCIENTIFIC) INC.; THOMSON REUTERS (SCIENTIFIC) LLC
To: THOMSON REUTERS (SCIENTIFIC) LLC
Reel/Frame 037211/0745 →
MERGER AND CHANGE OF NAME Recorded Nov 30, 2015
From: GENGO, INC.; THOMSON REUTERS (SCIENTIFIC) INC.
To: THOMSON REUTERS (SCIENTIFIC) INC.
Reel/Frame 037171/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2010
From: BUGRIM, ANDREJ; NIKOLSKAYA, TATIANA; MARKOV, ALEKSANDER
To: GENEGO, INC.
Reel/Frame 025184/0144 →